PLEXBIO CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.1 TWD | 0.00% |
|
+1.68% | -14.18% |
| 04-25 | PlexBio Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | PlexBio Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
| Sales 2022 | 191M 5.87M 8.01M | Sales 2023 | 167M 5.13M 7M | Capitalization | 1.46B 44.88M 61.19M |
|---|---|---|---|---|---|
| Net income 2022 | -53M -1.63M -2.22M | Net income 2023 | -58M -1.78M -2.43M | EV / Sales 2022 | 4.06 x |
| Net cash position 2022 | 473M 14.54M 19.82M | Net cash position 2023 | 417M 12.81M 17.46M | EV / Sales 2023 | 6.25 x |
| P/E ratio 2022 |
-23.5
x | P/E ratio 2023 |
-25.2
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 14.47% |
More Fundamentals
* Assessed data
More news
| 1 week | +1.68% | ||
| Current month | +0.41% | ||
| 1 month | -0.82% | ||
| 3 months | -11.68% | ||
| 6 months | -11.68% | ||
| Current year | -14.18% |
1 week
11.70
12.45
1 month
11.2012.45
Current year
11.2014.65
1 year
11.2019.45
3 years
11.2055.00
5 years
11.20115.00
10 years
11.20115.00
| Managers | Title | Age | Since |
|---|---|---|---|
Ting Tsao
CEO | Chief Executive Officer | - | 09-12-16 |
Chia Hung Hung
DFI | Director of Finance/CFO | - | 18-05-24 |
Li Pi Yeh
DFI | Director of Finance/CFO | - | 17-05-02 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Te Feng Tsao
BRD | Director/Board Member | 78 | 16-06-29 |
Ting Tsao
CEO | Chief Executive Officer | - | 09-12-16 |
Sonny Wang
BRD | Director/Board Member | - | 21-08-25 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 12.1 | 0.00% | 49,053 |
| 24-04-25 | 12.1 | +1.68% | 51,104 |
| 24-04-24 | 11.9 | -0.83% | 85,469 |
| 24-04-23 | 12 | +2.13% | 63,605 |
| 24-04-22 | 11.75 | -1.26% | 174,123 |
End-of-day quote Taipei Exchange, April 25, 2024
More quotes
PlexBio Co., Ltd. is a Taiwan-based company mainly engaging in provision of diversified testing equipment platform and multiple testing reagent. The Company's main products include medical testing equipment such as diversified in-vitro diagnostic (IVD) medical devices, reagents and others. The Company distributes its products within domestic markets and to overseas markets, including Taiwan, mainland China, American and other areas.
| 1st Jan change | Capi. | |
|---|---|---|
| -14.18% | 38.45M | |
| -2.15% | 187B | |
| -1.61% | 106B | |
| -3.85% | 66.9B | |
| +0.18% | 49.45B | |
| +16.30% | 48B | |
| +4.06% | 40.84B | |
| +3.44% | 26.48B | |
| +1.02% | 26.25B | |
| +12.96% | 24.62B |
- Stock Market
- Equities
- 6572 Stock
